Search research articles
Contact Us
Filters
Showing results (31-40 of 146) with videos related to
Page
of 15
Sort By:
HIV/AIDS (Auckland, N.Z.)
|
August 16, 2021
Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study
Gerrit Kann, Junaid Owasil, Karina Kuczka, et al.
Journal of the International AIDS Society
|
November 15, 2014
Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
Claus Philippe Küpper-Tetzel, Siri Göpel, Pavel Khaykin, et al.
European Journal of Clinical Pharmacology
|
December 25, 2009
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
Annette Haberl, Manfred Moesch, Gabriele Nisius, et al.
HIV Medicine
|
July 21, 2022
Sexually transmitted diseases in people living with HIV after implementation of cost coverage of HIV pre-exposure prophylaxis by statutory health insurance in Germany
Gundolf Schuettfort, Ana Groh, Gerrit Kann, et al.
International Journal of Medical Informatics
|
June 18, 2024
Exploring patient-centered design solutions of a telehealth app for HIV - A qualitative study
Jannik Schaaf, Timm Weber, Michael von Wagner, et al.
The Journal of Antimicrobial Chemotherapy
|
September 8, 2006
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
Schlomo Staszewski, Errol Babacan, Christoph Stephan, et al.
AIDS (London, England)
|
April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
Christoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Journal of the International AIDS Society
|
November 15, 2014
144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
Eva Wolf, Andreas Trein, Axel Baumgarten, et al.
Antiviral Therapy
|
February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
Nils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
Studies in Health Technology and Informatics
|
October 23, 2023
Enhancing HIV Patient Support Through Telehealth: Exploring Design Solutions
Richard Noll, Alexander Voigt, Susanne Koehler, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 146) with videos related to
Sort By:
Page
of 15
HIV/AIDS (Auckland, N.Z.)
|
August 16, 2021
Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study
Gerrit Kann, Junaid Owasil, Karina Kuczka, et al.
Journal of the International AIDS Society
|
November 15, 2014
Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
Claus Philippe Küpper-Tetzel, Siri Göpel, Pavel Khaykin, et al.
European Journal of Clinical Pharmacology
|
December 25, 2009
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
Annette Haberl, Manfred Moesch, Gabriele Nisius, et al.
HIV Medicine
|
July 21, 2022
Sexually transmitted diseases in people living with HIV after implementation of cost coverage of HIV pre-exposure prophylaxis by statutory health insurance in Germany
Gundolf Schuettfort, Ana Groh, Gerrit Kann, et al.
International Journal of Medical Informatics
|
June 18, 2024
Exploring patient-centered design solutions of a telehealth app for HIV - A qualitative study
Jannik Schaaf, Timm Weber, Michael von Wagner, et al.
The Journal of Antimicrobial Chemotherapy
|
September 8, 2006
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
Schlomo Staszewski, Errol Babacan, Christoph Stephan, et al.
AIDS (London, England)
|
April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
Christoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Journal of the International AIDS Society
|
November 15, 2014
144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
Eva Wolf, Andreas Trein, Axel Baumgarten, et al.
Antiviral Therapy
|
February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
Nils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
Studies in Health Technology and Informatics
|
October 23, 2023
Enhancing HIV Patient Support Through Telehealth: Exploring Design Solutions
Richard Noll, Alexander Voigt, Susanne Koehler, et al.
Page
of 15